{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"KeywordList": [["Benzo[g]quinazolinone", "EGFR", "HER2", "apoptosis", "benzenesulfonamide"]], "SpaceFlightMission": [], "InvestigatorList": [], "OtherAbstract": [], "OtherID": [], "CitationSubset": ["IM"], "GeneralNote": [], "PMID": "31074303", "DateCompleted": {"Year": "2019", "Month": "06", "Day": "10"}, "DateRevised": {"Year": "2020", "Month": "02", "Day": "25"}, "Article": {"ArticleDate": [], "Language": ["eng"], "ELocationID": ["10.1080/14756366.2019.1609469"], "Journal": {"ISSN": "1475-6374", "JournalIssue": {"Volume": "34", "Issue": "1", "PubDate": {"Year": "2019", "Month": "Dec"}}, "Title": "Journal of enzyme inhibition and medicinal chemistry", "ISOAbbreviation": "J Enzyme Inhib Med Chem"}, "ArticleTitle": "Novel sulphonamide benzoquinazolinones as dual EGFR/HER2 inhibitors, apoptosis inducers and radiosensitizers.", "Pagination": {"StartPage": "1030", "EndPage": "1040", "MedlinePgn": "1030-1040"}, "Abstract": {"AbstractText": ["A series of sulphonamide benzoquinazolinones 5-18 was synthesized\u00a0and evaluated for cytotoxic activity against MDA-MB-231 cell line. The compounds showed IC<sub>50</sub> ranging from 0.26 to 161.49\u2009\u00b5M. The promising compounds were evaluated for their inhibitory profile against epidermal growth factor (EGFR) and HER2 enzymes. Compound 10 showed more potent activity on both EGFR and HER2 than erlotinib (IC<sub>50</sub> 3.90 and 5.40\u2009\u00b5M versus 6.21 and 9.42\u2009\u00b5M). The pro-apoptotic activity of 10 was evaluated against caspase-3, Bax, B-cell lymphoma protein 2 (Bcl-2) expression levels, and cell cycle analysis. Compound 10 increased the level of caspase-3 by 10 folds, Bax level by 9 folds, decreased the level of the Bcl-2 by 0.14 and arrested the cell cycle in the G2/M phase. The radio-sensitizing activity of 10 was measured using a single dose of 8\u2009Gy gamma radiation (IC<sub>50</sub> decreased from 0.31 to 0.22\u2009\u00b5M). Molecular docking\u00a0was performed on EGFR and HER2 receptors."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "a Department of Drug Radiation Research , National Center for Radiation Research and Technology (NCRRT), Egyptian Atomic Energy Authority (EAEA) , Nasr City , Egypt."}], "LastName": "Soliman", "ForeName": "Aiten M", "Initials": "AM"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "b Department of Medicinal , Aromatic and Poisonous Plants Research Center (MAPPRC), College of Pharmacy, King Saud University , Riyadh , Saudi Arabia."}, {"Identifier": [], "Affiliation": "c Department of Pharmacognosy , College of Pharmacy, King Saud University , Riyadh , Saudi Arabia."}], "LastName": "Alqahtani", "ForeName": "Ali S", "Initials": "AS"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "a Department of Drug Radiation Research , National Center for Radiation Research and Technology (NCRRT), Egyptian Atomic Energy Authority (EAEA) , Nasr City , Egypt."}], "LastName": "Ghorab", "ForeName": "Mostafa", "Initials": "M"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "England", "MedlineTA": "J Enzyme Inhib Med Chem", "NlmUniqueID": "101150203", "ISSNLinking": "1475-6366"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Antineoplastic Agents"}, {"RegistryNumber": "0", "NameOfSubstance": "Protein Kinase Inhibitors"}, {"RegistryNumber": "0", "NameOfSubstance": "Quinazolinones"}, {"RegistryNumber": "0", "NameOfSubstance": "Radiation-Sensitizing Agents"}, {"RegistryNumber": "0", "NameOfSubstance": "Sulfonamides"}, {"RegistryNumber": "EC 2.7.10.1", "NameOfSubstance": "EGFR protein, human"}, {"RegistryNumber": "EC 2.7.10.1", "NameOfSubstance": "ERBB2 protein, human"}, {"RegistryNumber": "EC 2.7.10.1", "NameOfSubstance": "ErbB Receptors"}, {"RegistryNumber": "EC 2.7.10.1", "NameOfSubstance": "Receptor, ErbB-2"}], "MeshHeadingList": [{"QualifierName": ["chemical synthesis", "chemistry", "pharmacology"], "DescriptorName": "Antineoplastic Agents"}, {"QualifierName": ["drug effects"], "DescriptorName": "Apoptosis"}, {"QualifierName": ["drug effects"], "DescriptorName": "Cell Proliferation"}, {"QualifierName": [], "DescriptorName": "Cells, Cultured"}, {"QualifierName": [], "DescriptorName": "Dose-Response Relationship, Drug"}, {"QualifierName": [], "DescriptorName": "Drug Screening Assays, Antitumor"}, {"QualifierName": ["antagonists & inhibitors", "metabolism"], "DescriptorName": "ErbB Receptors"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": [], "DescriptorName": "Molecular Docking Simulation"}, {"QualifierName": [], "DescriptorName": "Molecular Structure"}, {"QualifierName": ["chemical synthesis", "chemistry", "pharmacology"], "DescriptorName": "Protein Kinase Inhibitors"}, {"QualifierName": ["chemical synthesis", "chemistry", "pharmacology"], "DescriptorName": "Quinazolinones"}, {"QualifierName": ["chemical synthesis", "chemistry", "pharmacology"], "DescriptorName": "Radiation-Sensitizing Agents"}, {"QualifierName": ["antagonists & inhibitors", "metabolism"], "DescriptorName": "Receptor, ErbB-2"}, {"QualifierName": [], "DescriptorName": "Structure-Activity Relationship"}, {"QualifierName": ["chemical synthesis", "chemistry", "pharmacology"], "DescriptorName": "Sulfonamides"}]}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972;26:239\u201357.", "ArticleIdList": ["PMC2008650", "4561027"]}, {"Citation": "Fischer U, Janssen K, Schulze-Osthoff K. Cutting-edge apoptosis-based therapeutics. Biodrugs 2007;21:273\u201397.", "ArticleIdList": ["17896835"]}, {"Citation": "Chen Z, Liang X, Zhang H, et al. . A new class of naphthalimide-based antitumor agents that inhibit topoisomerase II and induce lysosomal membrane permeabilization and apoptosis. J Med Chem 2010;53:2589\u2013600.", "ArticleIdList": ["20170164"]}, {"Citation": "Tian Z, Xie S, Du Y, et al. . Synthesis, cytotoxicity and apoptosis of naphthalimide polyamine conjugates as antitumor agents. Eur J Med Chem 2009;44:393\u20139.", "ArticleIdList": ["18423800"]}, {"Citation": "Bredesen DE. Apoptosis: overview and signal transduction pathways. J Neurotrauma 2000;17:801\u201310.", "ArticleIdList": ["11063049"]}, {"Citation": "DeSantis C, Ma J, Bryan L, Jemal A. Breast cancer statistics, 2013. CA Cancer J Clin 2014;64:52\u201362.", "ArticleIdList": ["24114568"]}, {"Citation": "Slamon DJ, Clark GM, Wong SG, et al. . Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177\u201382.", "ArticleIdList": ["3798106"]}, {"Citation": "Clauditz TS, Gontarewicz A, Lebok P, et al. . Epidermal growth factor receptor (EGFR) in salivary gland carcinomas: potentials as therapeutic target. Oral Oncol 2012;48:991\u20136.", "ArticleIdList": ["22694907"]}, {"Citation": "Arteaga CL, Engelman JA. ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics. Cancer Cell 2014;25:282\u2013303.", "ArticleIdList": ["PMC4018830", "24651011"]}, {"Citation": "Ohashi K, Sequist LV, Arcila ME, et al. . Characteristics of lung cancers harboring NRAS mutations. Clin Cancer Res 2013;19:1\u20138.", "ArticleIdList": ["PMC3643999", "23515407"]}, {"Citation": "Narayan M, Wilken JA, Harris LN, et al. . Trastuzumab-induced HER reprogramming in \u201cresistant\u201d breast carcinoma cells. Cancer Res 2009;69:2191\u20134.", "ArticleIdList": ["19276389"]}, {"Citation": "Olayioye MA, Neve RM, Lane HA, Hynes NE. The ErbB signaling network: receptor heterodimerization in development and cancer. Embo J 2000;19:3159\u201367.", "ArticleIdList": ["PMC313958", "10880430"]}, {"Citation": "Nagarsenkar A, Prajapti SK, Guggilapu SD, et al. . Investigation of triazole-linked indole and oxindole glycoconjugates as potential anticancer agents: novel Akt/PKB signaling pathway inhibitors. Med Chem Comm 2016;7:646\u201353."}, {"Citation": "Alsaid MS, Al-Mishari AA, Soliman AM, et al. . Discovery of benzo [g] quinazolin benzenesulfonamide derivatives as dual EGFR/HER2 inhibitors. Eur J Med Chem 2017;141:84\u201391.", "ArticleIdList": ["29028534"]}, {"Citation": "Ghorab MM, Alsaid MS, Soliman AM, Al-Mishari AA. Benzo[g]quinazolin-based scaffold derivatives as dual EGFR/HER2 inhibitors . J Enzyme Inhib Med Chem 2018;33:67\u201373.", "ArticleIdList": ["PMC6010119", "29098904"]}, {"Citation": "Elkamhawy A, Farag AK, Viswanath ANI, et al. . Targeting EGFR/HER2 tyrosine kinases with a new potent series of 6-substituted 4-anilinoquinazoline hybrids: design, synthesis, kinase assay, cell-based assay, and molecular docking. Bioorg Med Chem Lett 2015;25:5147\u201354.", "ArticleIdList": ["26475520"]}, {"Citation": "Zhang C, Li W. Regioselective synthesis of 6-aryl-benzo [h][1, 2, 4]-triazolo [5, 1-b] quinazoline-7, 8-diones as potent antitumoral agents. Bioorg Med Chem Lett 2013;23:5002\u20135.", "ArticleIdList": ["23871222"]}, {"Citation": "Schuler M, Yang JH, Park K, et al. . Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial. Ann Oncol 2016;27:417\u201323.", "ArticleIdList": ["PMC4769992", "26646759"]}, {"Citation": "Lee CK, Brown C, Gralla RJ, et al. . Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis. J Natl Cancer Inst 2013;105:595\u2013605.", "ArticleIdList": ["23594426"]}, {"Citation": "Pao W, Miller V, Zakowski M, et al. . EGF receptor gene mutations are common in lung cancers from \u201cnever smokers\u201d and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004;101:13306\u201311.", "ArticleIdList": ["PMC516528", "15329413"]}, {"Citation": "Yin S, Tang C, Wang B, et al. . Design, synthesis and biological evaluation of novel EGFR/HER2 dual inhibitors bearing a oxazolo [4, 5-g] quinazolin-2 (1H)-one scaffold. Eur J Med Chem 2016;120:26\u201336.", "ArticleIdList": ["27187856"]}, {"Citation": "Ghorab MM, El Ella DAA, Heiba HI, Soliman AM. Synthesis of certain new thiazole derivatives bearing a sulfonamide moiety with expected anticancer and radiosensitizing activities. J Mater Sci Eng A 2011;1:684\u201391."}, {"Citation": "El Ella DAA, Ghorab MM, Heiba HI, Soliman AM. Synthesis of some new thiazolopyrane and thiazolopyranopyrimidine derivatives bearing a sulfonamide moiety for evaluation as anticancer and radiosensitizing agents. Med Chem Res 2012;21:2395\u2013407."}, {"Citation": "Supuran CT, Scozzafava A. Carbonic anhydrase inhibitors. Curr Med Chem Immunol Endocr Metab Agents 2001;1:61\u201397."}, {"Citation": "Casini A, Scozzafava A, Supuran CT. Sulfonamide derivatives with protease inhibitory action as anticancer, anti-inflammatory and antiviral agents. Expert Opin Ther Pat 2002;12:1307\u201327."}, {"Citation": "Villar R, Encio I, Migliaccio M, et al. . activity of lipophilic sulphonamide derivatives of the benzo [b] thiophene 1, 1-dioxide. Bioorg Med Chem 2004;12:963\u20138.", "ArticleIdList": ["14980609"]}, {"Citation": "Payne JE, Bonnefous C, Hassig CA, et al. . Identification of KD5170: a novel mercaptoketone-based histone deacetylase inhibitor. Bioorg Med Chem Lett 2008;18:6093\u20136.", "ArticleIdList": ["18954983"]}, {"Citation": "Wurz RP, Liu L, Yang K, et al. . Synthesis and structure\u2013activity relationships of dual PI3K/mTOR inhibitors based on a 4-amino-6-methyl-1, 3, 5-triazine sulfonamide scaffold. Bioorg Med Chem Lett 2012;22:5714\u201320.", "ArticleIdList": ["22832322"]}, {"Citation": "Ghorab MM, Alsaid MS, Soliman AM, Ragab FA. VEGFR-2 inhibitors and apoptosis inducers: synthesis and molecular design of new benzo [g] quinazolin bearing benzenesulfonamide moiety. J Enzyme Inhib Med Chem 2017;32:893\u2013907.", "ArticleIdList": ["PMC6445170", "28661197"]}, {"Citation": "Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55\u201363.", "ArticleIdList": ["6606682"]}, {"Citation": "Emily HYC, Wei MC, Weiler S, et al. . BCL-2, BCL-X L sequester BH3 domain-only molecules preventing BAX-and BAK-mediated mitochondrial apoptosis. Mol Cell 2001;8:705\u201311.", "ArticleIdList": ["11583631"]}, {"Citation": "Alnemri ES, Livingston DJ, Nicholson DW, et al. . Human ICE/CED-3 protease nomenclature. Cell 1996;87:171.", "ArticleIdList": ["8861900"]}, {"Citation": "Harrington HA, Ho KL, Ghosh S, Tung K. Construction and analysis of a modular model of caspase activation in apoptosis. Theor Biol Med Model 2008;5:26\u201341.", "ArticleIdList": ["PMC2672941", "19077196"]}, {"Citation": "Ghavami S, Hashemi M, Ande SR, et al. . Apoptosis and cancer: mutations within caspase genes. J Med Genet 2009;46:497\u2013510.", "ArticleIdList": ["19505876"]}, {"Citation": "Rudel T. Caspase inhibitors in prevention of apoptosis. Herz 1999;24:236\u201341.", "ArticleIdList": ["10412648"]}, {"Citation": "Tsujimoto Y. Cell death regulation by the Bcl-2 protein family in the mitochondria. J Cell Physiol 2003;195:158\u201367.", "ArticleIdList": ["12652643"]}, {"Citation": "Hasnan J, Yusoff M, Damitri T, et al. . Relationship between apoptotic markers (Bax and Bcl-2) and biochemical markers in type 2 diabetes mellitus. Singapore Med J 2010;51:50\u20136.", "ArticleIdList": ["20200776"]}, {"Citation": "Callagy GM, Webber MJ, Pharoah PD, Caldas C. Meta-analysis confirms BCL2 is an independent prognostic marker in breast cancer. BMC Cancer 2008;8:153\u20138.", "ArticleIdList": ["PMC2430210", "18510726"]}, {"Citation": "McDonnell TJ, Korsmeyer SJ. Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14; 18)). Nature 1991;349:254\u20136.", "ArticleIdList": ["1987477"]}, {"Citation": "Zhu H, Zhang J, Xue N, et al. . Novel combretastatin A-4 derivative XN0502 induces cell cycle arrest and apoptosis in A549 cells. Invest New Drugs 2010;28:493\u2013501.", "ArticleIdList": ["20352291"]}, {"Citation": "MacLachlan TK, Sang N, Giordano A. Cyclins, cyclin-dependent kinases and cdk inhibitors: implications in cell cycle control and cancer. Crit Rev Eukaryot Gene Expr 1995;5:127\u201356.", "ArticleIdList": ["8845581"]}, {"Citation": "DeVita VT, Lawrence TS, Rosenberg SA. Cancer: principles & practice of oncology: primer of the molecular biology of cancer. Philadelphia, PA: Lippincott Williams & Wilkins; 2012."}, {"Citation": "Stamos J, Sliwkowski MX, Eigenbrot C. Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J Biol Chem 2002;277:46265\u201372.", "ArticleIdList": ["12196540"]}, {"Citation": "Ishikawa T, Seto M, Banno H, et al. . Design and synthesis of novel human epidermal growth factor receptor 2 (HER2)/epidermal growth factor receptor (EGFR) dual inhibitors bearing a pyrrolo [3, 2-d] pyrimidine scaffold. J Med Chem 2011;54:8030\u201350.", "ArticleIdList": ["22003817"]}, {"Citation": "Lin J, Shen W, Xue J, et al. . Novel oxazolo[4,5-g]quinazolin-2(1H)-ones: dual inhibitors of EGFR and Src protein tyrosine kinases. Eur J Med Chem 2012;55:39\u201348.", "ArticleIdList": ["22818848"]}, {"Citation": "Halmos B, Pennell NA, Fu P, et al. . Randomized phase II trial of erlotinib beyond progression in advanced erlotinib-responsive non-small cell lung cancer. Oncologist 2015;20:1298\u2013303.", "ArticleIdList": ["PMC4718423", "26306902"]}, {"Citation": "Yousuf Z, Iman K, Iftikhar N, Mirza MU. Structure-based virtual screening and molecular docking for the identification of potential multi-targeted inhibitors against breast cancer. Breast Cancer (Dove Med Press) 2017;9:447\u201359.", "ArticleIdList": ["PMC5476443", "28652811"]}]}], "History": [{"Year": "2019", "Month": "5", "Day": "11", "Hour": "6", "Minute": "0"}, {"Year": "2019", "Month": "5", "Day": "11", "Hour": "6", "Minute": "0"}, {"Year": "2019", "Month": "6", "Day": "14", "Hour": "6", "Minute": "0"}, {"Year": "2019", "Month": "5", "Day": "10"}], "PublicationStatus": "ppublish", "ArticleIdList": ["31074303", "PMC6522976", "10.1080/14756366.2019.1609469"]}}]}